Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, oral finasteride improved the quality of life for male patients with androgenetic alopecia, but it did not significantly reduce anxiety or correlate with reported anxiety levels.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This study found that finasteride caused adverse effects on liver, kidney, and heart tissues in female mice, raising concerns about its potential use in females for treating androgenetic alopecia.

This study concluded that two different pharmaceutical formulations of finasteride were bioequivalent in terms of rate and extent of absorption based on pharmacokinetic evaluations in a randomized crossover study with 38 volunteers.

In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.

This study found that progesterone pretreatment in rats potentiated the effect of ethanol on mesocortical dopamine levels, suggesting an influence of neuroactive steroids on ethanol's action.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study in Italy found that APS-1, a rare disorder, is associated with various AIRE gene mutations and most individuals have autoantibodies such as IFNωAbs, which are markers of the condition.

Finasteride slows down motherly behavior in first-time pregnant rats.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This study found that finasteride significantly improved hirsutism scores in women over 12 months and was well-tolerated with no serious side effects.

This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.

This study found that nearly half of men using finasteride reported clinically significant depression, highlighting the need for psychiatric screening and careful risk assessment by prescribing clinicians.

This review concluded that finasteride may reduce hirsutism scores and hair diameter in women with hyperandrogenism, but concerns about teratogenicity and long-term safety make it a secondary treatment option.

Finasteride and dutasteride increase sexual dysfunction reports.

This study found that both finasteride and flutamide effectively reduced hirsutism in women with polycystic ovary syndrome, decreasing the Ferriman-Gallwey score and hair diameter without significant side effects.

This study found that the pharmacological inhibition of 5-α reductases with finasteride and dutasteride can reduce neurosteroid synthesis in glioblastoma-derived cell lines, potentially impacting GBM survival.

This study found that male pattern hair loss worsened significantly after stopping finasteride, revealing a "rebound effect" where terminal hair transformed into miniaturized hair over 30 months off the drug.

This study found that young men using finasteride for androgenic alopecia exhibited erectile tissue fibrosis and associated sexual dysfunction, including low libido and mood changes.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

This study found that Transcutol P significantly enhanced the skin penetration of Finasteride in vitro, while cationic and anionic surfactants did not show such effects.

This research observed that finasteride-loaded ethosomes showed improved permeation across rat skin and human cadaver scalp skin compared to unencapsulated finasteride, potentially enhancing delivery to hair follicle units.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study found that oral administration of finasteride to pregnant rats caused dosage-related developmental toxicities, including hypospadias and decreased anogenital distance in male offspring.

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.

Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.

This study found that Diane 35 combined with finasteride led to a greater reduction in hirsutism scores over 12 months compared to Diane 35 alone.